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ABSTRACT 
Background: Four international study groups undertook a large study in 
resectable osteosarcoma, which included two randomised controlled trials, to 
determine the effect on survival of changing post-operative chemotherapy based 
on histological response. 
Patients and methods: Patients with resectable osteosarcoma aged ≤40 years 
were treated with the MAP regimen, comprising pre-operatively of two 5-week 
cycles of cisplatin 120mg/m2, doxorubicin 75mg/m2, methotrexate 12g/m2 x 2 
(MAP) and post-operatively two further cycles of MAP and two cycles of just MA. 
Patients were randomised after surgery. Those with ≥10% viable tumour in the 
resected specimen received MAP or MAP with ifosfamide and etoposide. Those 
with <10% viable tumour were allocated to MAP or MAP followed by pegylated 
interferon. Longitudinal evaluation of quality-of-life was undertaken. 
Results: Recruitment was completed to the largest osteosarcoma study to date 
in 75 months. Commencing March 2005, 2260 patients were registered from 326 
centres across 17 countries. 1334 of 2260 registered patients (59%) were 
randomised. Pre-operative chemotherapy was completed according to protocol in 
94%. Grade 3-4 neutropenia affected 83% of cycles and 59% were complicated 
by infection. There were 3 (0.13%) deaths related to pre-operative 
chemotherapy. At definitive surgery, 50% of patients had at least 90% necrosis in 
the resected specimen. 
Conclusions: New models of collaboration are required to successfully conduct 
trials to improve outcomes of patients with rare cancers; EURAMOS-1 
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demonstrates achievability. Considerable regulatory, financial and operational 
challenges must be overcome to develop similar studies in the future. 
 
The trial is registered as NCT00134030 and ISRCTN 67613327. 
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INTRODUCTION 
Osteosarcoma is the commonest primary bone cancer affecting young people 
with an overall age-standardised incidence rate of 5.2 cases/million[1]. Cure of 
osteosarcoma in a proportion of patients was consistently reported first in the 
1970s, achieved through the combination of surgical extirpation of the primary 
tumour with multi-drug chemotherapy. The results were further improved during 
the next decade, but since then, no clinically significant advances have been 
made in survival, although more patients access combination chemotherapy 
within and outside trials. 
 
In 2001, four clinical study groups agreed to collaborate to conduct 
osteosarcoma studies more rapidly. EURAMOS (European and American 
Osteosarcoma Studies) was formed from the Children’s Oncology Group (COG), 
Cooperative Osteosarcoma Study Group (COSS) of the German Society for 
Pediatric Oncology and Hematology (GPOH), European Osteosarcoma 
Intergroup (EOI) and Scandinavian Sarcoma Group (SSG). 
 
The EURAMOS group aimed to improve outcomes in osteosarcoma, principally 
through large international, collaborative randomised controlled trials (RCTs). 
Additional objectives were to facilitate biological research in osteosarcoma, more 
rapidly identify new therapeutic approaches, and develop a common 
understanding and methodologies for staging, pathology and other aspects of 
disease management.[2] 
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The first study, EURAMOS-1, began recruitment in 2005 and closed registration 
in Jun-2011. Good histological response, assessed in the resected tumour, has 
been associated with improved survival.[3-5] Therefore, this study addressed 
separate treatment questions based on histological response. EURAMOS-1 was 
notable for addressing randomised questions in a rare cancer on an 
unprecedented scale and for launching at a time of profound change to European 
legislation related to trial regulation and governance.[6] We describe the study, 
its population and the initial treatment of 2260 registered patients. 
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METHODS 
Patients 
We designed a clinical trial to include patients with newly-diagnosed localized or 
metastatic osteosarcoma† of the extremity or axial skeleton deemed to be 
suitable for complete resection of all disease sites. Patients were aged ≤40 years 
at diagnostic biopsy and had to both register on the study and start 
chemotherapy within 30 days after diagnostic biopsy. Patients required adequate 
bone marrow function (neutrophils ≥0.5x109/l or WBC ≥3x109/l; platelet count 
>100x109/l); renal function (glomerular filtration rate ≥70ml/min/1.73m2); liver 
function (bilirubin ≤1.5*upper limit of normal); cardiac function (shortening fraction 
≥28% or ejection fraction ≥50%); and performance status (Karnofsky score ≥60; 
WHO performance status <2; or Lansky score ≥60%). Standard staging and 
organ function investigations were undertaken. 
 
Diagnostic biopsies were to be examined by local institutional pathologists and 
reviewed by each study group’s reference pathologists. 
 
Study Design 
Figure_1 shows the design with randomisation defined by histological response 
in the primary tumour after pre-operative chemotherapy. Response classification 
was dichotomised: ≥90% necrosis (good response); <90% necrosis (poor 
response). Registered patients were offered randomisation when also had: 
                                                 
†
 See supplementary definitions 
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completed two courses of cisplatin and doxorubicin pre-operatively; completed 
≥2 (but ≤6) courses of methotrexate pre-surgery; recovered fully from prior 
therapy; no disease progression; undergone complete macroscopic resection of 
the primary tumour; and undergone complete removal of all metastatic disease or 
this was planned and deemed feasible. Patients with good histological response 
had to be ≥5yr due to concerns of age-related toxicity from interferon.[7] Data 
collection including registration characteristics and reports on pre-operative 
chemotherapy, surgery and pathology had to be received by the randomising data 
centre. Consent was obtained according to national regulations. 
Supp_Appendix_B describes the study organisation. 
 
Treatment 
Chemotherapy for the control arm (Figure_2) was based on the standard described 
in the previous largest RCT for osteosarcoma [8]. Pre-operative treatment 
comprised methotrexate 12g/m² (M), doxorubicin 75mg/m² (Adriamycin, A) and 
cisplatin 120mg/m² (P). Preferred schedules were 48-hour infusion for doxorubicin 
and either 72-hour infusion or two 4-hour infusions on separate days for cisplatin. 
Methotrexate was given over 4 hours and folinic acid rescue commenced at 24 
hours. Surgery was scheduled after two cycles of MAP, i.e. ten weeks after starting 
chemotherapy. 
 
Eligible, consenting patients with good histological response were randomised to 
complete 6 cycles of MAP or MAP followed by maintenance pegylated interferon 
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alpha-2b (Ifn; Merck) at 0.5–1.0μg/kg/week to 24 months after starting 
chemotherapy. Eligible, consenting patients with poor histological response were 
randomised to continue standard chemotherapy with MAP or to MAP/IE over 28 
weeks, a schedule designed to deliver the same total doses as post-operative MAP 
with additional ifosfamide and etoposide, agents previously demonstrating activity 
in osteosarcoma.[9] Ifosfamide 3000mg/m² x3 days, total dose 9g/m², was given 
with doxorubicin in cycles designated as Ai, and at 2800 mg/m² x5 days, total dose 
14g/m², with etoposide 100 mg/m² x5 days, designated IE cycles. 
 
The protocol detailed dose modifications to account for toxicity for all treatments. 
Granulocyte growth factors were recommended but not mandated. Dexrazoxane 
could be used at investigators’ discretion for reduced cardiac function remaining in 
the normal range; this applied throughout in N.America but was withdrawn by the 
European Medicines Agency in 2011. 
 
Response assessment was required to determine suitability for surgery and to 
exclude progression.‡ 
 
Quality-of-life evaluation 
Quality-of-life (QL) was assessed using self- and parent-completed questionnaires 
to determine short- and long-term impacts. For patients ≥16yrs, QL was assessed 
using EORTC QLQ-C30 questionnaire.[10] Patients <16yrs in COG centres 
                                                 
‡
 See supplementary definitions 
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answered the generic PedsQL questionnaire, and in Europe, PEDQOL.[11, 12] 
The initial QL assessment was at week 5, then 3m after definitive surgery, at 18m 
and 3yr after commencing therapy.  
 
Outcome measures 
The primary outcome measure was event-free survival (EFS), defined as time from 
randomisation to the first of: detection of local recurrence or metastases, 
progression of metastatic disease, detection of secondary malignancy, or death 
from any cause. EFS was chosen because prevention of first recurrence is the 
principal goal of adjuvant treatment for osteosarcoma, given the low rate of survival 
after first recurrence. Furthermore, treatment of recurrence is heterogeneous; 
treatment guidance for relapse accompanied the protocol, but sites’ existing 
standard practice was accepted. Secondary outcome measures were overall 
survival (OS), toxicity and quality-of-life. Toxicity was assessed using CTCAE 
version 3.0.[13] 
 
Sample size calculations 
We assumed 70% 3-year EFS on MAP for good response and 45% for poor 
response, timed from randomisation. Each sample size was based on 5% two-
sided significance level and 80% power. The Good Response randomisation 
needed 147 EFS events to detect improved 3-year EFS from 70% to 80% i.e. 
hazard ratio (HR)=0·63.[14] 5-year survival was estimated as 70% so long-term 
analyses for survival were planned for when 147 deaths are reported, for the same 
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relative and absolute improvements. For Poor Response, 378 events were targeted 
to detect improved 3-year EFS and 5-year OS from 45% to 55% (HR=0·75). 
 
We anticipated 45% (567) randomised patients would have good response and 
55% (693) poor response.[8] We planned to register ~1400 patients over 3.5 years 
to randomise 1260, assuming 10% non-randomisation for ineligibility or non-
consent. The observed non-randomisation rate was higher and the registration 
target was increased to ~2000. 
 
 
Statistical analysis 
This paper describes the full, registered patient population, including all patients 
who signed the informed consent documents, up to the point of surgery. Standard 
descriptive statistics are used. 
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RESULTS 
Study participants 
Between Apr-2005 and Jun-2011, 2260 patients from 326 sites in seventeen 
countries were registered (Supp_Figures_S1, S2); 1164 (52%) COG, 520 (23%) 
COSS, 457 (20%) EOI and 119 (5%) SSG. The majority of patients were aged 
10-19 with localised tumours of the lower limb (Table_1) and conventional type 
osteosarcoma on histology (Table_2a). Males comprised 59% (1330/2260) of the 
cohort; 355 (16%) had definite metastases, 161 (7%) possible and 1722 (77%) no 
metastases. Of 355 patients with definite metastases, 273 (77%) had lung mets 
only, 54 (15%) other mets only, 22 (6%) both lung-and-other, and 5 (1%) definite-
lung and possible-other mets. Of 161 patients with possible metastases, 144 (89%) 
had possible lung metastases, 11 (7%) possible other mets and 6 (4%) both. 
Table_1 shows baseline characteristics. 
 
The eligibility criteria spanned children and adults ≤40years old. We estimated 
accrual as a proportion of expected age-related osteosarcoma incidence 
osteosarcoma to address whether participation was equally likely within the study 
age range. In all groups, the proportion recruited from the estimated population fell 
from age≥15yrs in females and 19yrs in males, such that ~1/3 of potentially eligible 
patients were not registered (Supp_Figure_S3). Figure_3 shows the CONSORT 
diagram. 
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Randomisation 
Randomisation was offered to eligible registered patients with reported histological 
response. For those with reported good response, 69% (716/1040) accepted the 
relevant randomisation and for poor response, 58% (617/1059); one patient with 
good response was erroneously randomised to the poor response cohort and 
allocated MAP. The overall randomisation rate was 64% (1334/2100) for patients 
with known histological response. 
 
There was some variability in proportion randomised between groups: COSS 
363/520 (70%), SSG 82/119 (69%), EOI 276/457 (60%) and COG 613/1164 
(53%) (Supp_Table_S2). Patients aged 20-29yrs were less frequently 
randomised (106/199, 53%) than those 5-19yrs (1194/1995, 60%) or >30yrs 
(32/53, 60%). The main reason recorded for non-randomisation was absence of 
consent (413/2260, 18%). Progression prior to surgery was recorded in 176 
patients (8%). 88 patients (4%) could not be randomised because of late 
reporting of histology and 67 (3%) for incorrect pre-operative chemotherapy. 
Patient characteristics for randomised and non-randomised patients and by 
histological response are shown in Table_1. 
 
Histology 
Diagnosis was confirmed by reference pathologists in 2160/2209 (98%) of 
registered patients (Table_2). The commonest histological subtype was 
conventional (92%, 2033/2209), followed by telangiectatic (4%, 96/2209), small 
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cell (1%, 14/2209) and high-grade surface (1%, 29/2209). Thirty-one patients 
were deemed ineligible post-registration based on reference histological review 
of the biopsy. Biopsy details remain unavailable for 51 patients (2%). In 1917 
patients with reference pathologist assessment of both diagnostic biopsy and 
resected specimen, the classification was different for 75 (4%) patients. Of these, 
36/75 were re-classified as different subtypes of osteosarcoma, 15/75 as 
conventional, 13/75 as telangiectatic, 6/75 as high-grade surface osteosarcoma, 
and 5/75 were ineligible. 
 
Pathological assessment of histological response to pre-operative chemotherapy 
was available for 1975/2012 patients; 979 reported a good response and 996 a 
poor response. The response rate of good histological response to MAP was 
50% overall, ranging from 46% (433/949) COG, to 53% COSS (265/499), 53% 
SSG (58/110) and 54% EOI (223/417). 
 
Chemotherapy 
94% registered patients (2123/2248) completed two cycles of MAP pre-operatively. 
Median received pre-operative dose for doxorubicin was 149mg/m2 (target 
150mg/m2), 239mg/m2 cisplatin (target 240mg/m2) and 46.8g/m2 high-dose 
methotrexate (target 48g/m2). Median time from registration in EURAMOS-1 to 
starting chemotherapy was 0 days (interquartile range (IQR) -2; 0). Median time 
from start of chemotherapy to surgery was 82 days (IQR 76; 90). Median time 
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from surgery to starting post-operative chemotherapy for randomised patients 
was 18 days (IQR 14; 24). 
 
The pre-operative toxicities reported were as expected. Table_1b shows the 
worst reported toxicity. CTCAE grade 3-4 toxicity was common: 1863/2234 (83%) 
neutropenia; 1292/2237 (58%) infective complications; 1122/2238 (50%) 
thrombocytopenia; 544/1989 (27%) mucositis; grade 1 or 2 mucositis was 
reported in a further 21% (427/1989) and 28% (557/1989), respectively). Severe 
renal, neurological and left ventricular dysfunctions were uncommon. 
 
There were three treatment-related deaths (3/2260, 0.13%) during the pre-
operative period, two from infective complications and one from toxic epidermal 
necrolysis secondary to methotrexate. 
 
Surgery 
The amputation rate, including rotationplasty, was 17% (346/2054), ranging from 
16% (169/1045, COG) to 19% (22/114, SSG) (Table_3). Macroscopic clearance 
of the primary tumour was reported in 99% (2035/2051). There were 3 post-
operative deaths: one patient died from embolic complications on the third post-
operative day, a second from pneumonia with respiratory failure on day 29, and a 
third from infection complicated by multisystem failure 48 days after surgery. 
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Data completeness and follow-up 
Long-term event data were sought in all patients, regardless of randomisation. In 
15-Feb-2013, 1455/1566 (93%) had data within the previous 14 months; death 
and loss-to-follow-up were reported in 526/2260 and 168/2260 patients, 
respectively. Long-term event data from the full cohort, including second 
malignancy data, will be reported with further follow-up. 
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DISCUSSION 
Osteosarcoma therapy was revolutionized by the introduction of adjuvant 
combination chemotherapy, in the 1970s, but has improved little since. The cost 
of seeking cure is exceptionally high as patients receive particularly complex and 
toxic chemotherapy regimens, plus disabling surgery. The single new treatment 
which has emerged, mifamurtide (MTP-PE), has been the subject of 
considerable controversy and its availability varies internationally, due to 
disagreements about interpretation of the available clinical data and cost. 
 
While many studies have been undertaken for osteosarcoma, they are often 
characterised by being non-randomised or, if randomised, by their long accrual 
periods.[15-18] This was the background against which we joined together to 
attempt to develop new paradigms for treating this disease. 
 
The EURAMOS group chose to undertake a large cohort study, embedding two 
randomised comparisons as our first collaboration.[6] The two questions chosen 
for this first study stratified post-operative treatment according to the 
histologically-assessed response to pre-operative chemotherapy. It assessed 
maintenance therapy in patients with a better prognosis (Good response)[19] and 
intensification in patients with poorer prognosis (Poor response).[9, 20-22] These 
important questions were amenable to a relatively simple trial design. However, 
the agents chosen highlight the paucity of new or investigational products 
appropriate to include in phase III trials. 
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EURAMOS-1 has been successfully executed. The study was developed through 
a commitment to collaboration between four well-established study groups. With 
1334 patients with resectable osteosarcoma randomised, it doubled the size of 
the previous largest RCT in this population and accrual was completed in around 
6 years. Other indicators of quality and safety for a trial on this scale are 
reassuring. Concordance with protocol chemotherapy was excellent. Toxicities 
were consistent with previous experience of these agents. The treatment 
related-death rate of 0.18% from pre-operative chemotherapy is at the lower end 
of the range previously reported. 
 
In other areas, the study has highlighted where improvement is needed. This was 
the first publicly-funded pan-European clinical trial to be activated after European 
countries implemented the European Clinical Trials Directive, which created new 
challenges.[23] There were limits to the accessibility of the trial for osteosarcoma 
patients. We were unable to open EURAMOS-1 in some countries that wished to 
participate either because of regulatory constraints or insufficient funding. 
Moreover, even though we used age eligibility criteria which allowed inclusion of 
all patients aged <40yrs, the proportion of potentially eligible patients fell with 
increasing age beginning from late teenage years, a phenomenon consistent with 
accrual rates seen for other cancers in young adults.[24, 25] 
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The feasibility of delivering intensive chemotherapy for a rare cancer in multiple 
centres within a Good Clinical Practice framework is amply demonstrated here. 
However, it is also clear that the treatment burden of MAP is exceptionally high, 
reflected in levels of grade 3-4 haematological and non-haematological toxicity. 
While the link between increased toxicity and improved survival from 
osteosarcoma remains to be unravelled,[26] future approaches must look to 
reduce this burden as well as improve efficacy.  
 
At the time of trial planning, few data were available to guide a sample size 
calculation to accurately estimate randomisation rates and these were markedly 
lower than expected, which contributed to a decision to expand registration 
targets from 1400 to over 2000. Information collected on reasons for non-
randomisation has been relatively non-informative but anecdotally, young people 
expressed a reluctance to risk allocation to experimental treatments that were 
substantially longer than the standard MAP schedule. Further investigation of this 
important area is needed.[27] Greater patient involvement at the design stage 
may help in the future. 
 
First results of the Good Response randomisation have been presented 
orally,[28] with a clear demonstration that large-scale practice-changing 
randomised controlled trials can be undertaken in rare cancers by extending the 
traditional boundaries of collaboration. From EURAMOS-1, we are growing a 
wider collaboration with groups willing to work together. A successor study has 
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not yet emerged despite willingness by investigators and other trials groups 
joining the collaboration to face the formidable regulatory and financial 
challenges which must be overcome. The absence of testable new innovations in 
this disease is a cause for major concern and even more apparent now we have 
established a successful test platform. 
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